16 completed, 5 recruiting, 2 active not recruiting, 2 not yet recruiting. 13 Phase 2, 10 Phase 3, 2 Phase 4, 1 Phase 1.
Follow nemolizumab: new trials by email Literature Review of nemolizumab trials Research Report on nemolizumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis | Phase 3 | Recruiting | Galderma R&D | 240 | 2026-10-08 | 2026-10-16 |
| Nemolizumab for LS Nemolizumab 30 mg - Lichen Sclerosus of Vulva | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 25 | 2026-09-01 | 2026-07-15 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis Nemolizumab - Moderate-to-Severe Atopic Dermatitis | Phase 2 | Recruiting | Galderma R&D | 35 | 2026-07-13 | 2026-08-14 |
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis Nemolizumab, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Galderma R&D | 162 | 2026-02-20 | 2026-03-31 |
| Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. Nemolizumab - Lichen Plano-Pilaris | Phase 4 | Recruiting | The Skin Center Dermatology Group | 10 | 2026-02-01 | 2026-02-10 |
| Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) nemolizumab, Placebo - Chronic Pruritus of Unknown Origin | Phase 2 | Active not recruiting | Galderma R&D | 50 | 2025-10-20 | 2026-07-27 |
| Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Nemolizumab, CD14152 placebo - Moderate-to-severe Atopic Dermatitis | Phase 3 | Withdrawn | Galderma R&D | 2023-01-01 | 2023-09-21 | |
| Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe Nemolizumab - Healthy Volunteers | Phase 1 | Completed | Galderma R&D | 192 | 2022-08-11 | 2025-01-03 |
| An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis nemolizumab - Systemic Sclerosis | Phase 2 | Completed | Maruho Co., Ltd. | 6 | 2022-04-20 | 2026-02-13 |
| To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus Nemolizumab, Placebo - Chronic Kidney Disease Associated Moderate to Severe Pruritus | Phase 2 / Phase 3 | Completed | Galderma R&D | 258 | 2022-03-18 | 2026-05-01 |
| A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 34 | 2022-01-24 | 2024-10-08 |
| A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis Nemolizumab, CYP 450 Substrates - Atopic Dermatitis | Phase 2 | Completed | Galderma R&D | 17 | 2021-12-08 | 2024-12-05 |
| Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Nemolizumab - Moderate-to-Severe Atopic Dermatitis | Phase 2 | Completed | Galderma R&D | 109 | 2021-06-24 | 2026-06-25 |
| A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab - Prurigo Nodularis | Phase 3 | Active not recruiting | Galderma R&D | 500 | 2021-01-11 | 2025-11-12 |
| Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab 30 mg, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 286 | 2020-09-11 | 2024-07-10 |
| A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) Nemolizumab, Placebo - Prurigo Nodularis | Phase 3 | Completed | Galderma R&D | 274 | 2020-08-11 | 2024-07-10 |
| A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab Nemolizumab, Placebo - Dermatitis, Atopic | Phase 2 | Completed | Galderma R&D | 242 | 2020-03-05 | 2026-06-01 |
| Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis Nemolizumab - Moderate-to-Severe Atopic Dermatitis | Phase 3 | Completed | Galderma R&D | 1935 | 2019-12-30 | 2026-10-20 |
| Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis Placebo, Nemolizumab - Moderate-to-Severe Atopic Dermatitis | Phase 3 | Completed | Galderma R&D | 787 | 2019-06-30 | 2024-08-14 |
Showing 20 of 26. Sign in to see all of them.
Dermatitis, Atopic (12) · Pruritus (3) · Neurodermatitis (2) · Prurigo (2) · Psoriasis (2) · Scleroderma, Systemic (2) · Skin Diseases (2) · Eczema (1) · Lichen Planus (1) · Lichen Sclerosus et Atrophicus (1) · Lung Diseases, Interstitial (1) · Renal Insufficiency, Chronic (1) · Scleroderma, Diffuse (1) · Scleroderma, Limited (1) · Vulvar Lichen Sclerosus (1)
Galderma R&D (20) · Chugai Pharmaceutical (1) · Maruho Co., Ltd. (1) · Prof. Dr. Stephan Weidinger (1) · The Skin Center Dermatology Group (1) · University of California, San Francisco (1) · University of Texas Southwestern Medical Center (1)
United States (21) · Poland (11) · Germany (9) · Canada (7) · France (7) · Austria (6) · Hungary (6) · Spain (6) · South Korea (5) · Belgium (4) · Italy (4) · Netherlands (4) · Switzerland (4) · United Kingdom (4) · Australia (3)
Ayumi Yoshizaki, MD, PhD (1) · Melissa Mauskar, MD (1) · Raymond Cho, MD, PhD (1) · Ryosuke Mihara (1) · Stephan Weidinger, MD (1)
PMID 39008191, PMID 37888917, PMID 39067461, PMID 40116983, PMID 40266487, PMID 42693785, PMID 28249150, PMID 29753033, PMID 31449914, PMID 32074418, PMID 35088348, PMID 37615836, PMID 39068954, PMID 39602139, PMID 40360966, PMID 41081535, PMID 41405008, PMID 42771135
2019 (3), 2025 (1)